Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.33 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061622 | 0.81 | AADAT (0.40) | CYP11B2AADATCYP11B1GOT1OPRK1 | |
| SCHEMBL29500923 | 0.77 | SLC9A3 (0.38) | CYP11B2AADATNOTUMALDH1A1 | |
| SCHEMBL9851802 | 0.76 | CYP11B2 (0.41) | CYP11B2AADATCYP11B1OPRK1PDE4D | |
| SCHEMBL11778334 | 0.75 | CYP11B2 (0.54) | CYP11B2CYP11B1OPRK1PDE4DRIPK1 | |
| SCHEMBL21061364 | 0.72 | CYP11B2 (0.45) | CYP11B2CYP11B1AVPR1AOPRK1PDE4D | |
| SCHEMBL2340498 | 0.71 | AVPR1A (0.38) | CYP11B2AADATCYP11B1AVPR1AOPRK1 | |
| SCHEMBL5278269 | 0.71 | AVPR1A (0.38) | CYP11B2AADATCYP11B1AVPR1AOPRK1 | |
| SCHEMBL29500957 | 0.70 | ALDH1A1 (0.36) | CYP11B2CYP11B1RIPK1ALDH1A1 | |
| SCHEMBL29500932 | 0.70 | CYP1A2 (0.44) | CYP11B2AADATCYP11B1OPRK1PDE4D | |
| Hydrochloric Acid SCHEMBL5277480 | 0.70 | AVPR1A (0.38) | CYP11B2AADATCYP11B1AVPR1AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | CYP11B2 81/4885AADAT 886/4885CYP11B1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.